论文部分内容阅读
肝细胞肝癌(HCC)伴有门脉主干阻塞(MPV)一直是选择性肝动脉插管化疗栓塞(TACE)治疗的反指征。因为TACE治疗后的肝缺血可以导致肝功能衰竭。此对照研究旨在评估肝功能良好MPV周围有足够侧支的HCC患者行TACE后的安全性和有效性。 方法:47例伴MPV的HCC患者中31例(男26,女5,平均52.5±10岁)行TACE治疗,另16例(男13,女3,平均50.6±11.5岁)拒绝此疗法者作为对照组。两组的临床资料相仿。47例中弥漫型HCC占36例(77％),结节型HCC占11例
Hepatocellular carcinoma (HCC) with portal arterial obstruction (MPV) has been an anti-indicator of selective hepatic arterial chemoembolization (TACE) therapy. Because hepatic ischemia after TACE treatment can cause liver failure. This controlled study was designed to evaluate the safety and efficacy of TACE in HCC patients with adequate collaterals around MPV. METHODS: TACE was performed in 31 (26 males and 5 females, average 52.5±10 years) of 47 HCC patients with MPV, and another 16 (13 males and 3 females, mean 50.6±11.5 years) refused to use this therapy as Control group. The clinical data of the two groups are similar. In 47 cases, diffuse HCC accounted for 36 cases (77%), and nodular HCC accounted for 11 cases.